Contact the Board.
Arthur Brandwood has served the therapeutics industry for 40 years: in biomaterials and product R&D, as Director of Devices Registration and Assessment at TGA and through a business career spanning more than two decades including as Director and Principal Consultant of Brandwood CKC and a number of board and advisory roles.
At TGA Arthur was closely involved in the initial development of the current regulations for medical devices. He is actively engaged in Australian regulatory policy, including as past Chair of the National Advisory Board for AusMedtech with a leading role in dialogue with government. Internationally, Arthur provides training and advice to regulatory authorities and is Senior Adviser to the Asian Harmonization Working Party. He chairs The Standards Australia committee for biological and clinical evaluation of medical devices and is currently leading the revision of the ISO 10993-1 biological safety standard. His contributions have been recognised through an Outstanding Professional Contribution Award from China FDA and award of Fellow of the US Regulatory Affairs Professional Association.
Arthur is active in therapeutics innovation, serving as Director and Acting CEO of Ellen Medical and Director of Electrogenics. He is Visiting Professor in Biomedical Engineering at University of Sydney teaching regulatory affairs, and Honorary Fellow at University of Melbourne. He serves on the Industry Advisory Boards in biomedical engineering for both Universities.
Associate Professor Tam Nguyen has been a proud ARCS member and contributor over the last 8 years. Tam has numerous involvements in various ARCS activities including:
• Member of ARCS SCRuM Working Group
• Reviewer, ARCS Workforce Whitepaper
• Speaker, Sponsor at ARCS Conference and ARCS Annual Meeting in Melbourne (2017-2024)
• Instructor, ARCS Bootcamp – Medical Devices Program
Tam has over 25 years of working in the healthcare, health &medical research sector including tertiary teaching hospitals and medical research institutes across Australia. He is the Director of Research & Innovation at Monash Health - Victoria's largest public health service providing safe and high quality healthcare to 25% of Melbourne's population across the entire lifespan.
Tam serves as non-executive director on various NFP, healthcare and aged care boards for over 15 years. He also advises numerous medtech and health tech start-ups and sits on Investment Committee Horizon 3 Healthcare investment fund.
Tam is a Fellow of the Royal Society of Medicine, Royal Society of Public Health (UK), Australian Institute of Management and the Australasian Research Management Society
Tam currently holds academic appointments with Melbourne Medical School (Associate Professor), where he teaches the Master of Clinical Research and is an Adjunct Associate Professor at Monash Medical School.
He is a regular invited speaker on a broad range of topics in the Medtech and Pharma Sector. He chairs and moderates at numerous national and international conferences.
Anne O’Neill has transformed NSW’s health and medical research sector into a billion-dollar innovation engine for Australia and an international investment hub. Throughout her career, most notably as architect of the highly regarded Medical Devices Fund, Anne set the blueprint for collaboration between government and industry to drive innovation and commercialisation. She has built critically needed capacity through development programs and policies that support early stage researchers, founders, entrepreneurs and policymakers. A longtime champion for diversity, Anne is a key mentor and advocate for women and minority groups.
Anne holds a Bachelor of Science (Physiology and Pharmacology) (Hons) and an Executive Masters of Public Administration (ANZSOG). She is a Fellow of the Australian Academy of Technological Sciences and Engineering and was awarded the Public Service Medal in 2025.
John has worked in the health sector for the past 40 years in a variety of roles at a national level that has enabled a broad exposure to public and private healthcare delivery – in remote, regional and urban settings; community based care delivery and disability and aged care.
As a lawyer, he has chaired Codes of Conduct committees for both Medicines Australia and Medical Technology Association of Australia. John has been the national CEO of a large member based organisation and additionally has sat on a number of national member based Boards. He has been active internationally as a Council Member of the International Council of Nurses and a Director of the World Heart Federation.
Additionally, John has served on a number of Boards of charities including as Chair of the Smith Family and Unitingcare Ageing (NSW & ACT).
More recently, John has focussed on workforce issues (shortages, recruitment & retention strategies), training requirements, standard setting and the accreditation of programmes in RTO, TAFE and university settings.
John's board work includes a particular focus on governance and risk.
Ian is a globally experienced, senior leader with a track record of delivery across a broad range of geographical regions and therapeutics industry sectors. He has a strong understanding of what it takes to bring therapeutics products to market internationally as well as of the way other countries collaborate to develop their local life sciences ecosystems.
He is currently a Non-Executive Director of BioNSW and Chair of the Self-Care Sub-Committee for Consumer Healthcare Products Australia (CHPA). Ian also provides strategic advisory services and leadership coaching to clients across the life sciences sector in Australia and internationally – with a particular focus on the consumer healthcare sector and capability building for start-ups across the therapeutics industry.
Ian was previously the NSW Lead for the Medical Technology and Pharmaceuticals Sector within the AusIndustry Entrepreneur’s Programme – providing broad strategic advice and operational support for NSW based Small to Medium Enterprises and Start-ups.
Prior to this role, Ian spent more than 20 years with GlaxoSmithKline in a range of senior regional and global scientific leadership roles – his most recent role being Vice-President, Global Regulatory Transformation for the GSK/Pfizer Consumer Healthcare joint-venture. Ian’s experience prior to GSK included a decade in the UK and Switzerland with the Deloitte Life Sciences Management Consultancy Organisation and Novartis.
Ian has a Bachelors of Science (Honours) from the University of Sydney, a Master of Science from University of Surrey (UK), and an MBA from Macquarie University. He is a member of the Australian Institute of Company Directors.
Andrew Wiltshire is the Head of Healthcare Public Policy at Amazon Web Services APAC. He is an internationally experienced senior executive with a deep experience and expertise in healthcare business leadership and government relations, market access and external affairs. Andrew has a strong track record of business leadership and P&L management, and expertise and leadership in the development and execution of reimbursement and market access strategies. Andrew is passionate about healthcare with more than 30 years’ experience, and is a seasoned advocate personally engaging with government and other stakeholders on policy and market access.
Andrew chairs the Corporate Governance Committee.
Qiao is an experienced executive management and clinical research professional with over 20 years of industry experience in clinical research organisations, pharmaceutical companies, and academic institutions.
Over the years, Qiao has held in a number of roles in clinical, quality, project and people management. Qiao led a business unit that specialised in the delivery of early phase clinical trials that allowed her to work with a wide cross-section of the health sector and to promote the conduct of clinical trials in Australia.
Qiao enjoys building high performing teams and engaging stakeholders include clinicians, researchers, state and federal government agencies, c-suite executives, industry elites, biotech companies, and advocacy groups.
Amy is passionate about continuous learning, coaching and contributing to initiatives which improve efficiency and access to clinical research, including the Medicines Australia Research & Development Taskforce (RDTF), the Australian Clinical Trials Alliance (ACTA) and Transcelerate Biopharma.
Daniela is an experienced senior clinical research executive leader with over 20 years’ Life Sciences experience in Research institutes, Pharmaceutical companies and Contract Research Organisations. Daniela has strong expertise in clinical delivery, quality and compliance management, financial management, driving strategy and innovation and people leadership. Daniela is passionate about promoting clinical trials across the Asia Pacific region, with a particular focus on mentoring, advocacy and forging Industry and Academic collaborations to promote efficiencies and enhance capabilities for the clinical trial sector. Daniela holds a PhD in Chemistry from the Adelaide University and is a member of the Australian Institute of Company Directors.
Allira Hudson-Gofers is an experienced executive and governance professional, serving as Company Secretary for ARCS Australia. She brings over a decade of leadership experience across regulatory, health, legal, and innovation. A registered Trans-Tasman Patent Attorney and dual-degree qualified engineer, Allira is known for her strategic insight, operational rigour, and commitment to purpose-driven leadership.
Her career spans executive and board roles in professional services, medtech, and research, with a strong focus on risk, compliance, and stakeholder engagement. Allira holds current governance roles with the Australian Meat Processor Corporation and the International Women’s Forum Australia.
.png){kind=logo}
.png)
%20(2).jpg)
